B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

TY - JOUR

T1 - B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

AU - Infante, Maria Stefania

AU - Salmanton-García, Jon

AU - Fernández-Cruz, Ana

AU - Marchesi, Francesco

AU - Jaksic, Ozren

AU - Weinbergerová, Barbora

AU - Besson, Caroline

AU - Duarte, Rafael F

AU - Itri, Federico

AU - Valković, Toni

AU - Szotkovski, Tomáš

AU - Busca, Alessandro

AU - Guidetti, Anna

AU - Glenthøj, Andreas

AU - Collins, Graham P

AU - Bonuomo, Valentina

AU - Sili, Uluhan

AU - Seval, Guldane Cengiz

AU - Machado, Marina

AU - Cordoba, Raul

AU - Blennow, Ola

AU - Abu-Zeinah, Ghaith

AU - Lamure, Sylvain

AU - Kulasekararaj, Austin

AU - Falces-Romero, Iker

AU - Cattaneo, Chiara

AU - Van Doesum, Jaap

AU - Piukovics, Klára

AU - Omrani, Ali S

AU - Magliano, Gabriele

AU - Ledoux, Marie-Pierre

AU - de Ramon, Cristina

AU - Cabirta, Alba

AU - Verga, Luisa

AU - López-García, Alberto

AU - Da Silva, Maria Gomes

AU - Stojanoski, Zlate

AU - Meers, Stef

AU - Lahmer, Tobias

AU - Martín-Pérez, Sonia

AU - Dávila-Vals, Julio

AU - Van Praet, Jens

AU - Samarkos, Michail

AU - Bilgin, Yavuz M

AU - Karlsson, Linda Katharina

AU - Batinić, Josip

AU - Nordlander, Anna

AU - Schönlein, Martin

AU - Hoenigl, Martin

AU - Ráčil, Zdeněk

AU - Mladenović, Miloš

AU - Hanakova, Michaela

AU - Zambrotta, Giovanni Paolo Maria

AU - De Jonge, Nick

AU - Adžić-Vukičević, Tatjana

AU - Nunes-Rodrigues, Raquel

AU - Prezioso, Lucia

AU - Navrátil, Milan

AU - Marchetti, Monia

AU - Cuccaro, Annarosa

AU - Calbacho, Maria

AU - Giordano, Antonio

AU - Cornely, Oliver A

AU - Hernández-Rivas, José-Ángel

AU - Pagano, Livio

N1 - Copyright © 2022 Infante, Salmanton-García, Fernández-Cruz, Marchesi, Jaksic, Weinbergerová, Besson, Duarte, Itri, Valković, Szotkovski, Busca, Guidetti, Glenthøj, Collins, Bonuomo, Sili, Seval, Machado, Cordoba, Blennow, Abu-Zeinah, Lamure, Kulasekararaj, Falces-Romero, Cattaneo, Van Doesum, Piukovics, Omrani, Magliano, Ledoux, de Ramon, Cabirta, Verga, López-García, Da Silva, Stojanoski, Meers, Lahmer, Martín-Pérez, Dávila-Vals, Van Praet, Samarkos, Bilgin, Karlsson, Batinić, Nordlander, Schönlein, Hoenigl, Ráčil, Mladenović, Hanakova, Zambrotta, De Jonge, Adžić-Vukičević, Nunes-Rodrigues, Prezioso, Navrátil, Marchetti, Cuccaro, Calbacho, Giordano, Cornely, Hernández-Rivas and Pagano.

PY - 2022/10/3

Y1 - 2022/10/3

N2 - Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

AB - Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

U2 - 10.3389/fonc.2022.992137

DO - 10.3389/fonc.2022.992137

M3 - SCORING: Journal article

C2 - 36276116

VL - 12

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

M1 - 992137

ER -